*Inserm Unit 981, DHU TORINO, Gustave Roussy and University, Paris Sud, France; †Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; ‡Department of Translational Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; §Département de Pathologie et de Biopathologie, Centre Jean Perrin, Clermont-Ferrand, France; and EA 4766, ERTICa, Université d'Auvergne, Clermont-Ferrand, France; and ‖Inserm Unit 1030, DHU TORINO, Gustave Roussy and University Paris Sud, France.
J Thorac Oncol. 2014 Jan;9(1):7-17. doi: 10.1097/JTO.0000000000000028.
Cancer research has received a fresh impetus from the concept of cancer stem cell (CSC) which postulates the existence of a tumor cell population uniquely endowed with self-renewal capacity and therapy resistance. Despite recent progresses including targeted therapy, lung cancer treatment remains a challenge owing largely to disease recurrence. Providing a conceptual model of tumor resistance and disease relapse, the lung CSC has received extensive attention, leading to a flourishing literature and several ongoing clinical trials. In this study, we will discuss the data suggesting the existence of CSC in lung tumors and the potential clinical utility of CSCs as prognostic markers or cellular targets of new therapeutic strategies. We will also touch on the new fundamental developments of the CSC concept that ought to be considered if the integration of the CSC concept into clinical practice is to be successful and impact on lung cancer treatment.
癌症研究受到癌症干细胞 (CSC) 概念的新推动，该概念假定存在一种肿瘤细胞群体，具有独特的自我更新能力和治疗耐药性。尽管包括靶向治疗在内的最近进展取得了一定的成效，但由于疾病复发，肺癌的治疗仍然是一个挑战。肺癌 CSC 为肿瘤耐药和疾病复发提供了一个概念模型，引起了广泛关注，产生了大量文献和正在进行的临床试验。在本研究中，我们将讨论表明肺癌肿瘤中存在 CSC 的相关数据，并探讨 CSCs 作为预后标志物或新治疗策略的细胞靶点的潜在临床应用。我们还将涉及 CSC 概念的新基础发展，如果要成功将 CSC 概念整合到临床实践中并对肺癌治疗产生影响，这些发展都应该被考虑到。
